Last reviewed · How we verify
Antioxidant
Antioxidant, marketed by Maastricht University Medical Center, holds a niche position in the antioxidant therapeutic space. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports current market stability. The primary risk lies in the lack of clear revenue data and key trial results, which may limit investor confidence and market expansion.
At a glance
| Generic name | Antioxidant |
|---|---|
| Also known as | Capsule SM Fibro, Allopurinol (300mg daily),, ALA (600mg twice daily), nicotinamide (750 mg twice daily), Tea Tree oil (Tebodont®, Dr. Wild & Co. AG, Basel) |
| Sponsor | Maastricht University Medical Center |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity (PHASE2)
- Anti-Inflammatory Effects of Pecan Nut Oil Supplementation in Adults With Overweight: A Randomized Controlled Parallel-Group Clinical Trial (NA)
- Epigallocatechin Gallate (EGCG) as a Flushing Agent During Full Pulpotomy in Mature Permanent Molars With Irreversible Pulpitis (NA)
- Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women (PHASE1)
- Phenylalanine-free Diet for Patients With Secondary Hyperphenylalaninemia in ICU (NA)
- Novel Augmentation of DAOIB and Antioxidant for Early Dementia (PHASE2)
- Beetroot Beverage and Repeated Sprint Power Output During RAST (NA)
- Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |